Projects
This section presents pharmaceutical projects that are announced from time-to-time around the world.
Octapharma to Invest US$1.5 Billion in Rock Hill, South Carolina, USA
Octapharma has announced plans to invest US$15 billion to establish its first USbased manufacturing and production facility at Palmetto Research Park in Rock Hill, South Carolina
Bristol Myers Squibb to Invest US$2.3 Billion in Houston, Texas, USA
Bristol Myers Squibb has announced plans to invest approximately US$23 billion to develop a new manufacturing campus at Generation Park in Houston, Texas
Cambrex to Invest US$30 Million (€26 Million) in Milan, Italy
Cambrex has started construction of a new research and development RD facility at its Profarmaco Milano site in Milan, Italy, as part of a US$30 million 26 million investment
Evonik to Invest US$100 Million in Lafayette, Indiana, USA
Evonik has announced plans to invest US$100 million over five years to upgrade drug substance manufacturing infrastructure at its Tippecanoe Labs site in Lafayette, Indiana
BeOne Medicines to Invest US$300 Million in Hopewell, New Jersey, USA
BeOne Medicines has announced plans to invest US$300 million to expand its manufacturing and research and development site at the Princeton West Innovation Campus in Hopewell, New Jersey
Johnson & Johnson to Invest US$1 Billion in Jacksonville, Florida, USA
Johnson Johnson has announced plans to invest more than US$1 billion to expand vision manufacturing, packaging and distribution infrastructure in Jacksonville, Florida
Novartis to Invest US$23 Billion in Denton, Texas, USA
Novartis has announced plans to invest US$23 billion to establish a new radioligand therapy manufacturing facility in Denton, Texas
CSL to Invest US$1.5 Billion in Illinois, USA
CSL has announced an investment of US$15 billion to expand its plasmaderived therapies manufacturing facility in Kankakee, Illinois, USA
ESTEVE CDMO to Invest US$15.5 Million in Illinois, USA
ESTEVE CDMO has announced an investment of US$155 million to expand and upgrade its small molecule active pharmaceutical ingredient API manufacturing facility in Morton Grove, Illinois, USA
PharmaEssentia to Invest US$46 Million in Puerto Rico, USA
PharmaEssentia has announced an investment of approximately US$46 million to establish a new manufacturing facility in Toa Baja, Puerto Rico, USA
